For canine atopic dermatitis (cAD), no single agent is universally first-line — the 2015 ICADA guidelines and 2023 AAHA guidelines both recommend a multimodal approach, with drug selection driven by disease phase (acute flare vs. chronic maintenance), severity, and individual patient response.BMC Veterinary…+1

For acute flares, oclacitinib and glucocorticoids are the primary interventions. Oclacitinib (0.4–0.6 mg/kg PO q12h for 14 days, then q24h) produces onset of pruritus relief within 1 hour and reduces dermatitis and pruritus scores by 48.4% at days 14–28, compared to a 1.7% reduction with placebo.Journal of the… By day 7, 70.5% of oclacitinib-treated dogs achieve ≥50% reduction from baseline in pruritus, dermatitis, and pruritus visual analog scale (PVAS) scores, versus 23.2% with placebo.Journal of the… Prednisolone (0.5–1.0 mg/kg PO q24h for 6 days, then every other day) produces comparable reductions in pruritus and dermatitis at most time points, with the exception of day 14, when oclacitinib reductions are more pronounced.Journal of the… Oclacitinib is effective within 1 hour; prednisolone requires approximately 10 hours to reduce pruritus and is ineffective at the 1-hour mark.Journal of the… Up to one-third of dogs do not achieve satisfactory control with oclacitinib, underscoring the need for alternatives.Veterinary Derm…

Ilunocitinib (0.6–0.8 mg/kg PO q24h, administered with or without food) is a newer Janus kinase inhibitor (JAKi) that demonstrates better clinical outcomes than oclacitinib across multiple efficacy parameters and offers the advantage of continuous once-daily dosing without the regimen change required for oclacitinib at day 14.Veterinary Derm…

For chronic maintenance, ciclosporin and lokivetmab are the primary long-term options alongside continued oclacitinib. Ciclosporin requires 4–6 weeks to reach maximal efficacy.AAHA Clinical G… Adverse events occur in 55% of dogs in clinical trials, though gastrointestinal reactions are the most common and are typically mild; serious adverse events are rare at pharmacovigilance rates of 71.81 events per million capsules sold.Veterinary Reco… Ciclosporin decreases concurrent Staphylococcal and Malassezia infections in atopic dogs and is not a risk factor for neoplasia, renal failure, or hypertension at recommended doses.Veterinary Reco… Routine monitoring of complete blood counts, urinalysis, or ciclosporin levels is not justified except at higher-than-recommended doses or with concurrent long-term immunosuppressive drugs.Veterinary Reco… Live vaccines should be avoided during treatment, though killed vaccines including rabies are not contraindicated.Veterinary Reco…

Lokivetmab prevents flares when administered before allergen challenge and has positive effects on skin barrier parameters. In direct comparison, oclacitinib and lokivetmab both preserve skin hydration and prevent increases in transepidermal water loss (TEWL), while ciclosporin and prednisone do not — TEWL increases significantly in the ciclosporin group (axilla, day 28 vs. day 0) and skin hydration decreases in the prednisone group (axilla, day 14 vs. day 0).Veterinary Derm… Hydration area under the curve over time is higher for lokivetmab and oclacitinib than for untreated controls.Veterinary Derm…

Allergen-specific immunotherapy (ASIT) is the only treatment with the potential to normalize the dysregulated immune response and reduce long-term medication requirements, but clinical benefit may not appear for up to 6–12 months and it is ineffective in some dogs.Journal of the… ASIT is effective in approximately 50–100% of canine patients.AAHA Clinical G… Intralymphatic immunotherapy (ILIT) achieves return to normal status (CADESI <12, PVAS <2.5, medication score <10) in 60% of dogs at 12 months, compared to 17% with subcutaneous immunotherapy (SCIT) and 14% with sublingual immunotherapy (SLIT); CADESI and PVAS improve significantly with ILIT and SCIT but not SLIT.Veterinary Derm… ASIT is best managed in consultation with a board-certified dermatologist.Journal of the…+1

Chronic glucocorticoid monotherapy carries significant long-term risk — polyuria, polydipsia, polyphagia, skin atrophy, and iatrogenic hyperadrenocorticism — and is not recommended as the sole long-term treatment, though it remains appropriate when other options are cost-prohibitive or the patient is glucocorticoid-responsive only.Journal of the…+1

Adjunctive topical therapy is recommended at all disease stages. Bathing with moisturizing shampoos (containing fatty acids, oatmeal, ceramides, or lipids) reduces allergen load, pruritus, and secondary infection burden.AAHA Clinical G… An Ophytrium-containing shampoo and leave-on mousse protocol added to stable systemic therapy achieves CADESI-04 remission (score <10) in 47.1% of dogs and pruritus remission (PVAS <2) in 32.4% of dogs at 21 days.Journal of Smal…

Would you like a breakdown of how to sequence these options when a dog has an inadequate response to oclacitinib monotherapy?